PuraPharm Dividendos y recompras

Dividendo controles de criterios 0/6

PuraPharm no paga actualmente dividendo.

Información clave

Rentabilidad por dividendo

Rendimiento de la recompra

Rendimiento total para el accionista	0%
Rendimiento futuro de los dividendos	n/a
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	HK$0.0202
Ratio de pago	0%

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

Feb 06

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de 1498 han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de 1498 han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de PuraPharm vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de 1498 con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (1498)	0%
Suelo de mercado 25% (HK)	3.1%
Techo de mercado 25% (HK)	7.9%
Media de la industria (Pharmaceuticals)	3.7%
Analista de previsiones (1498) (hasta 3 años)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de 1498 en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de 1498 en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: 1498 no paga un dividendo notable para el mercado Hong Kong.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que 1498 no ha comunicado ningún pago.

PuraPharm Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

First half 2024 earnings released: HK$0.047 loss per share (vs HK$0.095 loss in 1H 2023)

PuraPharm Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

PuraPharm Corporation Limited to Report First Half, 2024 Results on Aug 28, 2024

PuraPharm Corporation Limited has withdrawn its Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited has filed a Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited, Annual General Meeting, May 24, 2024

PuraPharm Corporation Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2023 earnings released: HK$0.095 loss per share (vs HK$0.10 loss in 1H 2022)

PuraPharm Corporation Limited to Report First Half, 2023 Results on Aug 29, 2023

Less than half of directors are independent

PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director

Full year 2022 earnings released: HK$0.30 loss per share (vs HK$0.31 loss in FY 2021)

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

First half 2022 earnings released: HK$0.10 loss per share (vs HK$0.03 profit in 1H 2021)

PuraPharm Corporation Limited to Report First Half, 2022 Results on Aug 27, 2022

Purapharm Corporation Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Founder recently bought HK$118k worth of stock

Less than half of directors are independent

Purapharm Corporation Limited Announces Retirement of Non-Executive Director

Full year 2021 earnings released: HK$0.31 loss per share (vs HK$0.086 profit in FY 2020)

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ending December 31, 2021

Investor sentiment improved over the past week

Founder recently bought HK$86k worth of stock

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

CFO & Company Secretary Ka Kuen Lau has left the company

Independent Non-Executive Director Kin Keung Chan has left the company

Executive Vice-Chairman Kam Biu Tsoi has left the company

Non-Executive Director Kin Man Chan has left the company

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm Corporation Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day high: HK$0.80

New 90-day high: HK$0.78

Founder recently bought HK$54k worth of stock

New 90-day low: HK$0.66

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

PuraPharm Corporation Limited Appoints Norimoto Hisayoshi as Executive Director, Effect from 17 November 2020

First half earnings released

Founder recently sold HK$9.5m worth of stock

New 90-day high - HK$0.80

Earnings released

PuraPharm Corporation Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day low - HK$0.60

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Descubre empresas que pagan buenos dividendos